IVISbrite™ D-Luciferin Ultra Bioluminescent Substrate in RediJect™ Solution (RediJect D-Luciferin Ultra K+ salt) is a novel bioluminescent in vivo substrate in a ready-to-use pre-formulated injectable format that includes a fluorescent marker to validate your substrate injection.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
IVISbrite D-Luciferin Ultra Bioluminescent Substrate in RediJect Solution is pre-formulated with a fluorescent marker to validate your substrate injection. With PerkinElmer’s IVISbrite D-Luciferin Ultra you can ensure reproducible results by minimizing variability due to formulation and substrate injection, minimizing freeze/thaw and controlling batch to batch variation.
IVISbrite D-Luciferin Ultra is pre-formulated with a rapidly clearing fluorescent dye to validate the integrity of your substrate injection, so with a quick fluorescent image on your IVIS system you know immediately if an injection failed and you can normalize your bioluminescence results. With IVISbrite D-Luciferin Ultra RediJect bioluminescent substrate, you can have extra confidence in your data quality.
|Product Brand Name||IVISbrite|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Blue Ice|
|Unit Size||10 vials|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
XenoLight RediJect D-Luciferin Ultra in ready-to-use injectable format
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.